Cloned Blood-brain Barrier Adenosine Transporter is Identical to the Rat Concentrative Na+ Nucleoside Cotransporter CNT2
Overview
Endocrinology
Neurology
Authors
Affiliations
Adenosine transport into brain is regulated by the activity of the adenosine transporter located at the brain capillary endothelial wall, which forms the blood-brain barrier (BBB) in vivo. To facilitate cloning of BBB adenosine transporters, poly A+ RNA was purified from isolated rat brain capillaries for production of a rat BBB cDNA library in the pSPORT vector. The cloned RNA (cRNA) generated from in vitro transcription of this library was injected into frog oocytes followed by measurement of [3H]-adenosine uptake. After dilutional cloning, a full-length, 2905-nucleotide adenosine transporter cDNA, designated clone A-11, was isolated. The A-11 clone yielded [3H]-adenosine flux ratios of 400 to 500 after injection of cRNA in oocytes. The adenosine uptake was sodium-dependent and insensitive to inhibition by S-(4-nitrobenzyl)-6-thioinosine (NBTI). The Km and Vmax of adenosine transport in the cRNA-injected oocytes were 23.1 +/- 3.7 micromol/L and 10.8 +/- 0.9 pmol/oocyte. min. The K0.5 for sodium was 2.4 +/- 0.1 mmol/L, with a Hill coefficient (n) of 1.06 +/- 0.07. DNA sequence analysis indicated the rat BBB A-11 adenosine cDNA was identical to rat concentrative nucleoside transporter type 2 (CNT2). The adenosine transporter activity of the rat BBB A-11 CNT2 clone is 50-fold more active than previously reported rat CNT2 clones. In summary, these studies describe the expression cloning of CNT2 from a rat BBB library and show that the pattern of sodium dependency and NBTI insensitivity of the cloned CNT2 are identical to patterns of adenosine transport across the BBB in vivo. These results suggest that BBB adenosine transport in vivo is mediated by CNT2, which would make CNT2 one of the few known sodium-dependent cotransporters that mediate substrate transport across the BBB in the blood to brain direction.
Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies.
Jamabo M, Mahlalela M, Edkins A, Boshoff A Int J Mol Sci. 2023; 24(15).
PMID: 37569903 PMC: 10420020. DOI: 10.3390/ijms241512529.
3D In Vitro Blood-Brain-Barrier Model for Investigating Barrier Insults.
Wei W, Cardes F, Hierlemann A, Modena M Adv Sci (Weinh). 2023; 10(11):e2205752.
PMID: 36782313 PMC: 10104638. DOI: 10.1002/advs.202205752.
A Historical Review of Brain Drug Delivery.
Pardridge W Pharmaceutics. 2022; 14(6).
PMID: 35745855 PMC: 9229021. DOI: 10.3390/pharmaceutics14061283.
Cysteine Donor-Based Brain-Targeting Prodrug: Opportunities and Challenges.
Ni G, Hu Z, Wang Z, Zhang M, Liu X, Yang G Oxid Med Cell Longev. 2022; 2022:4834117.
PMID: 35251474 PMC: 8894025. DOI: 10.1155/2022/4834117.
The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier.
Pardridge W Front Physiol. 2020; 11:398.
PMID: 32457645 PMC: 7221163. DOI: 10.3389/fphys.2020.00398.